[Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].

Oxidative stress may play a critical role in the pathogenesis of endothelial dysfunction in patients with diabetes or hypertension. An angiotensin II type 1 receptor(AT1) antagonist candesartan is now a widely used antihypertesive drug, and AT1 activation is a predominant source of oxidative stress. We studied the effect of a 12-week treatment of candesartan(4-12 mg-day) on oxidative stress markers [lipid peroxidation(LPO), malondialdehyde-modified LDL(MDA-LDL), 8-epi-PGF2 alpha, and the generation of superoxide anion by monocytes(CLA-DCL)] in 30 type 2 diabetic patients with hypertension (> 140/85 mmHg). Both MDA-LDL and CLA-DCL were significantly decreased, although the others were not changed. These data suggest that candesartan clinically improves oxidant stress, probably lowering the generation of superoxide anion from blood monocytes.